`Tel: 571-272-7822
`
`Paper 80
`Entered: June 21, 2021
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`PFIZER
`
`INC.,!
`Petitioner,
`
`V.
`
`NOVO NORDISK A/S,
`Patent Owner.
`
`IPR2020-003247
`Patent 8,114,833 B2
`
` ÿÿ
`ÿ
`
`
` ÿ
` ÿÿÿÿ
`ÿ
` ÿÿ
`ÿ
`ÿÿ
`
` ! "ÿ# $ #ÿ$ ÿ$ "ÿ %$"&$%'ÿ())!*ÿ
`++++++++++++ÿ
`ÿ
`,)(%ÿ -ÿ$ ÿ %!$.ÿ$ "ÿ$$.ÿ,($%"ÿ
`++++++++++++ÿÿ
`)!/%ÿ! *ÿ
`
` ÿÿ ÿÿ
` (0(ÿ (%"!#'ÿ$1#ÿ
` ÿ(2 ÿ
`++++++++++++ÿ
`ÿ
`!%34ÿ
` ÿ433ÿ,ÿ
`++++++++++++ÿ
`ÿ
`ÿ,5
` ÿ%!*$ÿ$ÿ)%$ '.! ÿ(- ÿ6ÿ 7ÿ ÿÿ
`##$ ÿ.ÿ*ÿ&! *-..ÿ89:;<;=>?@>;ABÿD@>B<>ÿEF9GB=Hÿ
`ÿ)%$ '.! ÿ89:;<;=>?@>;ABÿD@>B<>ÿEF9GBÿ
`ÿÿ
`(%"%ÿ
`6
` ÿ&
`
`ÿ
`ÿ I ÿ Jÿ
`K
` ÿ%L ÿ
`ÿ
` ÿ# I ÿ"
`KI ÿ ÿ,ÿ*
`5 ÿ!5
` I
`ÿÿ
`MNÿOHPHQÿRÿMSTÿ
`ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ
`ÿ Jÿ
`K
`ÿ Jÿ
`
` ÿ&V ÿ
`!
` ÿ..*ÿÿ ÿWÿ
`ÿ!%ÿJ ÿUÿX
`ÿ2 Jÿ Jÿ
`K
`
`ORDER
`Joint Motion to Terminate the
`and Joint Request
`Proceeding
`Granting
`Treat Settlement Documents as Business Confidential Information
`35 U.S.C $ 317
`
`Before ERICA A. FRANKLIN, JOHN G. NEW,and
`SUSANL. C. MITCHELL, Administrative Patent
`Judges.
`
`FRANKLIN,Administrative Patent
`
`Judge.
`
`to
`
`'
`
`This proceeding has been terminated asto the original petitioner, Mylan
`Institutional LLC. Paper 67.
`2
`IPR2020-01252 has been joined with this proceeding. Paper 33.
`
`
`
`IPR2020-00324
`Patent 8,114,833 B2
`
`With authorization of the Board, Novo Nordisk A/S
`(“Patent Owner”)
`filed a
`motion to terminate the
`and Pfizer Inc.
`
`(“Petitioner Pfizer’’)
`joint
`77. Patent Ownerfiled a true copy
`
`proceeding. Paper
`settlement agreement under seal. Ex. 2102.
`filed a
`
`oftheir written
`
`with authorization
`
`was
`
`proceeding
`
`Mylan
`
`Mylan
`
`because
`
`they
`
`agreementthat settled their
`
`andall
`
`between
`
`joint
`reached an
`
`them
`
`involving
`we
`
`Additionally,
`joint request that the settlement agreement
`from the Board, the
`parties
`be treated as business confidential information and
`kept separate from the
`file of US Patent No. 8,114,833 B2
`(Ex. 1001, “the ’833
`patent”). Paper 78.
`The Decision on Institution for this
`was entered on June
`proceeding
`23, 2020. Paper 12. The Decision on Institution of IPR2020-01252 and
`Petitioner Pfizer Inc.’s Motion for Joinder with this
`Granting
`proceeding
`entered on December4, 2020. Paper 33. On March 26, 2021, the
`parties
`at an oral
`hearing. Paper 51. Thereafter, with
`presented arguments
`filed a
`authorization from the Board, Patent Ownerand Petitioner
`as to Petitioner
`motion to terminate the
`
` ÿÿ
`
`
`ÿ ÿ ÿ
`ÿ
`
`ÿ
`
`
`ÿ ÿÿÿ ÿ!"
`
`ÿ#$
`
`
`
`ÿ+
`
`ÿ
`+
`ÿ
`ÿ
`,'
`
`ÿ#$
`ÿ',/ÿÿ
`ÿ$
`
`
`
`
`)+
`ÿ -+
`ÿ
`
`ÿ
`
`
`+ÿ
`ÿ ÿ
`ÿ,
`ÿ)ÿ ÿ*
`ÿ2
`ÿ
`
`ÿ
`ÿ
`
`)+
`ÿ -+
`ÿ
`3ÿ
`
`ÿ ÿ3
` )ÿ
`
`ÿ,
`ÿ+ÿ
`ÿ
`)ÿÿ4 ÿ
`
`ÿ(ÿ ÿ ÿ!01(ÿÿ"
`ÿ5 ÿ,
`
`%&(ÿÿ ,ÿ. (ÿÿÿ
`6ÿ7'
`
`
`
`ÿ,'
`ÿ
` ÿ (ÿÿ ,ÿ (ÿÿ6ÿ7'
`
`
`
`:
`
`
`
`
`ÿ
`ÿ,'
`
`ÿ
`ÿ,
`ÿ
`,
`ÿ -+
`ÿ
`ÿ
`ÿ$
`ÿ
`
`
`
`ÿ ÿ
`
`ÿ#$
`
`
`*
`ÿ+
`
`ÿ
`+
`ÿ
`ÿ,'
`ÿ
`
`
`/ÿ
` 'ÿ
`ÿ
`
`ÿ
`
`)ÿ
`ÿ,
`ÿ
`-
`
`$
`
`+ÿ
`ÿ5 ÿ,
`
`(ÿÿ ,ÿ<<ÿ=<(ÿÿÿ
`ÿ
`
`ÿÿ
` 3ÿ$ÿ-
`ÿ
`ÿ6+
`
`ÿ
`
`
` ,ÿ<.(ÿÿ#
`
`ÿ +ÿ
`ÿ
`
`
`
`ÿ#$
`ÿ
`
`
`
`ÿ)ÿ ÿ+
`
`ÿ
`+
`ÿ
`ÿ,'
`
`
`ÿ+
`
`ÿ*
`ÿ2
`ÿ
`ÿ
`
`ÿ
`ÿ
`
`)+
`ÿ -+
`ÿ
` ÿ3
` )ÿ
`
`ÿ,ÿ
`ÿ,
`ÿ+ÿ
`ÿ)ÿÿ
`
`ÿ5 ÿ,
`
`(ÿÿÿ
` ÿ
`
`dispute
`litigation
`the ’833 patent. Paper 66, 1-6. As noted in footnote 1,
`on
`the Termination as to Petitioner
`April 16, 2021.
`above,
`Mylan
`granted
`Paper 67. On that same
`date, Petitioner Pfizer and Patent Owner
`requested
`authorization to file a motion to terminate the
`We now consider
`
`proceeding.
`to treat their settlement agreement
`that motion,
`joint request
`as business confidential information and to
`
`as well as their
`
`the ’833 patent.
`
`keep
`
`it separate from thefile of
`
`
`
`dispute concerning
`they
`to moveto terminate this
`
`agreed
`
`Ex.
`
`The
`
`proceeding
`that there is no
`
`(citing
`district court
`
`appropriate
`the ’833 patent and have
`in full. Mot. 2
`
`IPR2020-00324
`Patent 8,114,833 B2
`
`The
`
`parties
`
`assert that their
`
`requested
`
`because
`
`havesettled their
`
`termination is
`
` ÿÿ
`
`
`ÿ ÿ ÿ
`ÿ
`ÿÿ
`ÿ
`ÿ
`
`ÿ
`ÿ
`ÿ
`
`
`ÿ
` ÿ
`ÿ ÿ
`
` ÿ
`ÿ
`ÿ
`ÿ" ÿ
`
`ÿ
` !ÿ
`ÿÿ
`ÿ
`
`ÿ
`ÿ
`$ÿ ÿ&
`
`'($ÿ )$ÿÿÿ
`ÿ(
`
`ÿ
`ÿÿ
`
`ÿ
`ÿ
`
`!
`
`*
`ÿ
`
`ÿ
`ÿ" ÿ
`
`$ÿÿ+,-ÿ
`ÿ$ÿÿ.
`
`
`ÿ
`ÿ
`
`ÿ
`ÿ
`
`ÿ
`ÿ
`!
`
`*
`
`ÿ/*
`
`ÿ" ÿ
`
`ÿ$$ÿ0121ÿ014,567ÿ+89-ÿ:;ÿ<=-ÿ2-ÿ>?=<8ÿ
`+86;5;@;518<=ÿAABÿC$.$ÿD$ÿEFFÿ&G$ÿG $)ÿ* ÿ ÿÿ ÿ
`
`
`
`ÿ
`*
`ÿ
`ÿ
`ÿ
`ÿ
` $ÿÿ+,-ÿÿI
`ÿ
`ÿ
`ÿ
` ÿ
`ÿ
`
`ÿ
`ÿ ÿ ÿ
`ÿÿ ÿ
`#
`
`
`ÿ
`J
`ÿ
`
`ÿ
`
`ÿ#!
`
`ÿ
`ÿ*ÿ
`
`
`ÿ ÿ
`
`
`
`ÿ
`$ÿÿÿ
`K
`O P
`ÿÿ
`
`*
`ÿ
`
`ÿ*
` ÿ
`
`
` ÿ !
`ÿ#ÿ
`ÿ
`ÿ !
`ÿÿ
`
`
`ÿÿ
`
`
`
`ÿ
`
`
`ÿ
`ÿ*ÿ
`
`ÿ
`
`
`ÿÿ#ÿÿ !
`ÿ
`ÿ
`
`ÿ/##ÿ#ÿ
`ÿ
`
`
`
`ÿ
`ÿ
`ÿ*ÿ ÿ
`*
`ÿ
`$ÿ
`ÿQ::ÿ<=61ÿNÿC$I$$ÿMÿ $N&)ÿ&R.
`ÿÿ
`
`*
`
`ÿ
`ÿ ÿ
`
`ÿÿ
`
`
`ÿ
`
`
`#ÿ ÿ
`
`ÿÿ ÿÿ# ÿ*
`ÿ
`ÿ
` ÿ#ÿ
`ÿ
`
`
`ÿ
` $S)$ÿÿ.ÿ
`ÿ ÿ
`ÿ
`ÿ# ÿ
` ÿ
`
`
`ÿ !
`ÿ
`
`ÿ
`ÿ
`ÿT
`ÿ
`
`
`ÿ
`#ÿ
`
`ÿR'(
`ÿ ÿÿ ÿ
`ÿ
`ÿÿ#ÿ
`ÿL
`
`
`ÿ
`ÿ
`
`proceeding
`appropriate.
`Under35 U.S.C. § 317(b),
`or
`owner and
`between the patent
`[a]ny agreement
`understanding
`a
`petitioner, including any collateral agreements referred to in
`or
`made in connection with,or in
`such agreement
`understanding,
`contemplation of, the termination of an inter partes review under
`and a true copy of such agreement
`this section shall be in
`writing
`or
`shall be filed in the Office before the
`understanding
`termination ofthe inter partes review as between the
`
`2102).
`parties explain
`pending
`between them that involves the ’833 patent. Jd. at3.
`confirm that the district court
`between Patent Owner
`litigation
`the ’833 patent, 1.e., Novo Nordisk Inc. et al. v.
`Mylan involving
`was resolved
`Institutional LLC, C.A. No. 19-cv-01551
`
`litigation
`
`parties
`
`the
`
`and
`
`settlement between those
`
`parties
`
`(D. Del.),
`the court on
`
`and dismissed
`
`Additionally,
`
`Mylan
`a
`
`by
`
`April 6,
`by
`note that the Board has not issued a
`
`2021. Jd. Further, the
`
`parties correctly
`
`final written decision in this
`
`proceeding.
`
`Jd.
`
`Having
`
`considered the circumstances involvedin this
`
`proceeding,
`we determine that a
`
`including
`
`the
`
`foregoing
`
`assertions of the
`
`parties,
`
`termination of the
`
`is
`
`parties.
`
`See also 37 C.F.R. § 42.74(b) (“Any agreementor
`understanding
`or in
`made in connection with,
`the
`contemplation of, the termination
`and a true copyshall
`be filed with the
`As noted above, the
`In their
`
`writing
`proceeding
`Board before the termination ofthe
`a settlement agreement relating
`joint motion,
`proceedings.
`that “Exhibit 2102 is a true and
`complete copy of the Settlement
`
`parties
`of a
`
`shall be in
`
`trial.”).
`to these
`
`they certify
`
`3
`
`between
`
`parties
`
`filed
`
`
`
`In accordance with the
`
`ORDEREDthat the
`
`joint
`
`it is
`
`foregoing,
`hereby:
`motion to terminate the
`
`proceeding
`
`is
`
`granted;
`FURTHER ORDEREDthatthis inter partes review is terminated;
`
`and
`
`FURTHER ORDEREDthatthe
`
`joint request that the settlement
`agreement, Ex. 2102, be treated as business confidential information and
`kept separate from the file of the ’833 patent is
`
`granted.
`
`IPR2020-00324
`Patent 8,114,833 B2
`
`Agreement, and there are no other written or oral agreements
`between Pfizer and Novo Nordisk that are made in
`
`or
`
`proceeding.”
`
`parties
`
`317(b).
`
`ORDER
`
`understandings
`or in
`contemplation of, the termination of the instant
`connection with,
`we determinethat the
`Mot. 2. Based on that understanding,
`havesatisfied section
`
` ÿÿ
`
`
`ÿ ÿ ÿ
`ÿ
`
`ÿ
`ÿ ÿ
`ÿ
`
`
`ÿÿ
`
`
`
`
`ÿ ÿ ÿ
`#
`
`ÿÿ
`$
`
`ÿ
`
`
`ÿ
`
`ÿ
`$#
`%ÿ %ÿÿ ÿ
`
`ÿ
`
`
`
`ÿ
`ÿ
`$
`ÿ !ÿ
`ÿ#
`
`ÿ
`,-.ÿ
`ÿ
`ÿ
`ÿ
`ÿÿ/0ÿ
`,-..-ÿ
`
`ÿ
`ÿ1
`ÿ
`
`ÿ
`
`ÿ
`ÿ$#
`23456789ÿÿ:;<=.ÿ,-..-ÿ
`
`ÿ
`ÿ>5673ÿ?4367@ÿ!ÿÿ673A>546789ÿ
`
`
`ÿ
`ÿ1
`ÿB
`ÿ
`
`ÿ
`ÿ
`
`
`ÿ
`
`ÿ.C%ÿ ÿÿ
`
`ÿ ÿ
` ÿ
`
`"$
`ÿ$
`ÿÿ
`ÿÿÿ
`ÿD ÿ$
`
`ÿÿ2345678%ÿ
`ÿÿ
`ÿ
`ÿ
`
`
`
`IPR2020-00324
`Patent 8,114,833 B2
`
`For PETITIONER PFIZER INC:
`
`Thomas J. Meloro
`
`tmeloro@willkie.com
`
`Michael W. Johnson
`
`mjohnson1 @willkie.com
`
` ÿÿ
`
`
`ÿ ÿ ÿ
`ÿ
`ÿ ÿ ÿ ÿ
`ÿ ÿ ÿ!"ÿ
`
`
`"#$%""&% 'ÿ
`ÿ!%' "ÿ( ÿ
`
`)
`ÿÿ *ÿ(ÿ+ÿ, -.ÿ*/-ÿ
`ÿ001ÿ"&ÿ
`)"�
`ÿ1
`1
`ÿ2 3 ÿ!
`2 3
`
`Ryan Johnson
`Ryan.johnson@fenwick.com
`
`For PATENT OWNER NOVO NORDISKA/S:
`
`Oelke
`
`Jeffrey
`joelke@fenwick.com
`
`Laura Moran
`
`Laura.moran@fenwick.com
`
`ÿ
`
`